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Abstract
Background: To simplify the adaptive treatment planning workflow while achieving the optimal tumor-dose coverage
in pancreatic cancer patients undergoing daily adaptive magnetic resonance image guided radiation therapy (MR-IGRT).
Methods: In daily adaptive MR-IGRT, the plan objective function constructed during simulation is used for plan re-
optimization throughout the course of treatment. In this study, we have constructed the initial objective functions
using two methods for 16 pancreatic cancer patients treated with the ViewRay™ MR-IGRT system: 1) the conventional
method that handles the stomach, duodenum, small bowel, and large bowel as separate organs at risk (OARs) and 2)
the OAR grouping method. Using OAR grouping, a combined OAR structure that encompasses the portions of these
four primary OARs within 3 cm of the planning target volume (PTV) is created. OAR grouping simulation plans were
optimized such that the target coverage was comparable to the clinical simulation plan constructed in the conventional
manner. In both cases, the initial objective function was then applied to each successive treatment fraction and the plan
was re-optimized based on the patient’s daily anatomy. OAR grouping plans were compared to conventional plans at
each fraction in terms of coverage of the PTV and the optimized PTV (PTV OPT), which is the result of the subtraction of
overlapping OAR volumes with an additional margin from the PTV.
Results: Plan performance was enhanced across a majority of fractions using OAR grouping. The percentage of
the volume of the PTV covered by 95% of the prescribed dose (D95) was improved by an average of 3.87 ± 4.29%
while D95 coverage of the PTV OPT increased by 3.98 ± 4.97%. Finally, D100 coverage of the PTV demonstrated an
average increase of 6.47 ± 7.16% and a maximum improvement of 20.19%.
Conclusions: In this study, our proposed OAR grouping plans generally outperformed conventional plans, especially
when the conventional simulation plan favored or disregarded an OAR through the assignment of distinct weighting
parameters relative to the other critical structures. OAR grouping simplifies the MR-IGRT adaptive treatment planning
workflow at simulation while demonstrating improved coverage compared to delivered pancreatic cancer treatment
plans in daily adaptive radiation therapy.
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Background
Magnetic resonance image guided radiation therapy
(MR-IGRT) systems (MRIdian System; ViewRay™ Inc.,
Oakwood Village, OH) have been successfully implemented
at a number of institutions in recent years and used to treat
a growing group of patients that benefit from the
advantages offered by Magnetic Resonance Imaging (MRI)
compared to other conventional image guiding modalities
(e.g. CBCT, x-ray radiography) [1, 2]. Anatomical variations
from simulation to treatment as well as fraction to fraction
represent a challenge in the delivery of radiation therapy, as
changes in the size and position of target and critical struc-
tures can affect dose delivery in a clinically significant way
[3–12]. The improved visualization of soft tissues gained
from an MRI system compared to traditional cone-beam
CT (CBCT) systems allows for the daily management of
these inter-fraction anatomical variations, especially in areas
of extensive soft tissue like the abdomen [1, 13]. It is this
improved soft tissue visualization that makes adaptive
radiation therapy (ART) an attractive application of the
MR-IGRT system [1, 14, 15]. The implementation of ART
does come at the cost of an increased time investment for
plan re-optimization, however, which reflects the time
consuming nature of inverse treatment planning in
radiation therapy [1, 16].
Inverse planning involves the assignment of weighting
parameters to target and critical structures that control
the balance between delivering the prescribed dose to
the target and protecting healthy tissues [17–23]. The
selection of these parameters is recognized as a challen-
ging undertaking that involves a “guessing game” of re-
peated trial and error in a “human iteration loop.” [22–
26] This process becomes more complex and time con-
suming as the number of important structures and asso-
ciated parameters involved in a plan grows, highlighting
the need for a simpler treatment planning workflow [25,
27].
In pancreatic cancer cases specifically, a group of four
structures – the stomach, duodenum, small bowel, and
large bowel – represent organs at risk (OARs) of
particular importance [28, 29]. The present study pro-
poses the use of a single OAR structure that combines
these four primary OARs, restricting the number of asso-
ciated weighting parameters by a factor of four and
thereby simplifying the treatment planning process. The
aim of the study is to simplify the daily adaptive treatment
planning workflow in the treatment of pancreatic cancer
using the ViewRay™ System while maintaining tumor
coverage that is robust to inter-fraction anatomical
variations. The conventional daily adaptive treatment
planning workflow is described along with the OAR
grouping method, and comparative dosimetric data for 16
pancreatic cancer patients treated with daily adaptive MR-
IGRT is presented.
Methods
Sixteen pancreatic cancer patients previously treated
with daily adaptive MR-IGRT were used as test cases,
representing 208 adapted fractions. The volumes of the
planning target volume (PTV), the contours of which
are held constant throughout treatment for each patient,
ranged from 57.7 cm3 to 356.3 cm3 with an average of
160.5 cm3. Clinically delivered treatment plans were
used as a baseline for comparison at each fraction. The
OAR grouping method was compared to the baseline in
three metrics [1]: Percentage of the PTV covered by 95%
of the prescribed dose (D95) [2]; D95 coverage of the
PTV OPT; and [3] Percentage of the PTV covered by
100% of the prescribed dose (D100).
OAR grouping method
In the conventional treatment plan, each OAR is handled
separately. Weighting parameters are assigned to each of
these critical structures as well as the target as inputs to
the objective function, which is the aggregate of the cost
functions for individual structures involved in planning.
Figure 1 illustrates the simple formulation of the cost
function f(D| θ) used in this study for both OARs and the
target, where D is the delivered voxel dose and θ is the set
of weighting parameters assigned to a structure. For OARs
(Fig. 1a), the cost increases for a given delivered dose D
once a selected threshold T is exceeded. The shape of the
curve is controlled using an importance factor ω and
power u. Similarly, the cost for a dose D delivered to the
target (Fig. 1b) increases as the dose deviates from the
prescribed dose D0 plus a selected offset. The curves for
doses above and below this threshold are shaped using
importance and power parameters as discussed for the
OAR case.
The creation of the initial objective function involves
tuning each one of these parameters in order to achieve
a plan of acceptable quality. In a pancreatic cancer
treatment plan, each of the four primary OARs is subject
to the same volumetric dose constraint (Table 1), so any
variation in the assignment of weighting parameters is
likely a reflection of the position of an OAR relative to
the PTV. The OAR grouping method creates a single
OAR structure by combining the portions of the
stomach, duodenum, small bowel, and large bowel
within 3 cm of the PTV. Using OAR grouping, the
shared dose constraint is maintained, but the objective
function is simplified by restricting the number of
parameters used as inputs.
Simplification of objective function
The value of the proposed method is derived from a
simplification of the dose optimization function:
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f total Djθð Þ ¼
Xk
i¼1
f ci Djθið Þ þ f t Djθtð Þ; ð1Þ
where the cost f is a function of the delivered dose D
and weighting parameters θi = {ωi, ui,Ti} for all critical
structures and θt = {ωlt, ωut, lt, ut,D0, offset} for the target
structure (Fig. 1). In the conventional pancreas treat-
ment plan, the stomach, duodenum, small bowel, and
large bowel each carry individual weighting parameters
including upper importance ω, upper power u, and
threshold T. Additionally, the target carries lower
parameters for importance and power, ωl and l respect-
ively, as well as a prescribed dose D0 and corresponding
offset. In this conventional case, the set of all weighting
parameters for critical structures and the targetθ = {ω1,
u1,T1,…, ωk, uk,Tk, ωlt, ωut, lt, ut,D0, offset} is quite large.
The OAR grouping method combines the four primary
critical structures, and as a result [1] becomes
f total Djθð Þ ¼ f c Djθcð Þ þ f t Djθtð Þ
þ
Xl
j¼1
f r−OAR Djθ j
 
; ð2Þ
where θc + t = {ωc, uc,Tc, ωlt, ωut, lt, ut,D0, offset} represents
the reduced set of weighing parameters for the four
combined primary critical structures and the target and
θj represents the weighting parameters of any remaining
OARs (r-OAR) that may be included in the plan, such as
the spinal cord or kidneys.
Simulation
The conventional workflow for simulation has been
previously described in detail [1, 15]. Briefly, patients
undergo CT and MRI scans on the simulation day using
the same setup device. Then, the MR images are sent to
either the ViewRay™ treatment planning system or
third-party software (e.g. Eclipse™) for the structure
delineation. The corresponding structure sets, MR images,
and CT scans are then combined and fused into the
ViewRay™ treatment planning system for plan creation.
Treatment isocenter, number of beam entries, and beam
angles are defined by the planners such that the plan is
physically deliverable with respect to the couch position.
Finally, the prescribed dose and dose constraints on
critical organs are used to guide the selection of weighting
parameters input to the objective function for the IMRT
plan optimization.
In this study, the conventional simulation plan was
copied for each patient to keep the same beam entry and
physical setup (treatment isocenter, couch position, etc.)
in order to maintain as fair a comparison as possible.
Using the OAR grouping method, portions of the stomach,
duodenum, small bowel, and large bowel within 3 cm of
the PTV were combined into a single OAR structure. This
combined structure was then used in place of the individual
critical structures in constructing the simulation objective
function. The OAR grouping simulation plan was created
and optimized such that the target coverage, OAR
Fig. 1 Representative cost functions plotted for an OAR (a) and the target structure (b), along with the associated weighting parameters
Table 1 Volumetric dose constraints observed in pancreatic cancer
treatment plans. Each of the four primary OARs is subject to
the same volumetric constraint of less than 0.5 cm3 receiving a
maximum dose of 45 Gy
Structure Volume Measure Max Dose (Gy)
Stomach < 0.5 cm3 45
Duodenum < 0.5 cm3 45
Small Bowel < 0.5 cm3 45
Large Bowel < 0.5 cm3 45
Spinal Cord = 0 cm3 40
Kidneys < 50% 15
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doses, and beam-on time were comparable to the
conventional plan.
Daily adaptive MR-IGRT
In daily adaptive MR-IGRT, the volumetric MRI of the
patient is scanned before each treatment fraction. After
critical structures are re-contoured, the plan is re-
optimized based on the patient’s daily anatomy using the
same objective function constructed in the pretreatment
simulation plan, all while the patient remains on the
couch. In the present study, the conventional plan at
each treatment fraction was copied and modified using
the OAR grouping method. For the purposes of
comparison, all plans – both conventional and OAR
grouping – were normalized to satisfy one of two
scenarios, whichever came first: 1) the primary OAR
receiving the greatest volumetric dose received a dose of
45 Gy to 0.5 cm3, or 2) the dose to the spinal cord or
kidneys met the dose constraints as outlined in Table 1.
Results
The percentage of fractions improved in each metric out
of 208 total fractions for all patients is presented in
Table 2. Generally, the coverage is improved across a
majority of fractions when OAR grouping is utilized over
the conventional method. Greater than 70% of fractions
showed improvement in PTV OPT coverage, while
approximately 80% of all fractions demonstrated
improved PTV coverage using OAR grouping.
In Fig. 2, PTV and PTV OPT D95 coverage relative to
the prescription of 95% target volume coverage by D95 is
plotted as a cumulative histogram. Figure 2 illustrates
that PTV coverage fails to meet the prescription in
nearly 100% of the adapted fractions due to the close
proximity of surrounding OARs. The benefits of the
proposed method can be more clearly understood when
examining coverage of the PTV OPT, which is
comprised of portions of the PTV not overlapped by
OARs. In the conventional case, only 22% of all fractions
exhibited PTV OPT coverage that met the prescription.
When the OAR grouping method is utilized, that ratio
increases to 42% of all fractions. It should be noted that
the high ratio of under-covered fractions demonstrates
the challenge of treating pancreatic cancer. In a majority
of cases, the PTV is overlapped to some extent by
surrounding OARs. In these cases, target coverage is
often compromised in order to satisfy the dose
constraints assigned to these critical structures.
Average coverage across a patient’s total adapted
fractions is presented for each patient in Table 3 for both
the conventional and OAR grouping plans. Similarly,
Table 4 contains the average improvement of OAR
grouping plans compared to conventional plans along
with the minimum and maximum observed improve-
ments across all patients. D95 coverage of the PTV and
PTV OPT was improved by an average of approximately
4%, while PTV D100 coverage demonstrated an average
improvement of greater than 6%. The relatively large
standard deviations in each case are due to data points
well above the mean, which can be observed for each
metric in Fig. 3.
Discussion
In the present study, the OAR grouping method was
applied to pancreatic cancer cases with the aim of
simplifying the daily adaptive MR-IGRT treatment
planning workflow while maintaining target coverage
that is robust to inter-fraction anatomical variations. In
this way, the value of the proposed method is twofold.
First, the simplification of the initial treatment planning
process is easily understood. Reducing the number of
OARs involved in planning restricts the set of weighting
parameters that must be tuned iteratively to create an
acceptable plan. Second and more important, the
observed improvements in target coverage over a majority
of fractions demonstrate the benefits of the method. The
creation of the combined OAR structure makes the
objective function created at simulation somewhat
insensitive to significant changes in a patient’s anatomy
from fraction to fraction. In the conventional plan, the
weighting parameters selected at simulation may not
accurately reflect the patient’s anatomy at a later treatment
Table 2 Percentage of fractions in which coverage was improved
using OAR grouping. Total = 208 fractions
PTV OPT D95 PTV D95 PTV D100
Fractions Improved (%) 73 78 84
Fig. 2 Cumulative histogram that demonstrates the ratio of total
fractions receiving target coverage relative to the prescription of
95% target volume coverage by D95
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fraction. As a result, surrounding OARs may be overdosed
and target coverage will suffer. In the proposed plan, the
combined OAR structure lessens the impact of large
differences in anatomy between simulation and treatment.
Although the individual OARs may change position rela-
tive to the PTV, the position of the composite structure
relative to the PTV changes less dramatically. As a result,
the weighting parameters assigned at simulation more
accurately reflect the present anatomy and target coverage
is improved compared to the conventional case.
A number of general trends were observed for individual
patients as well as the cohort as a whole. Regarding the
weighting selections made in conventional plans, two
general situations are relevant. For plans in which an OAR
was favored or disregarded by the conventional objective
function through higher or lower weighting respectively,
OAR grouping plans generally performed better in terms
of coverage. Included as an illustrative example, Fig. 4
includes one slice from simulation (Fig. 4a) and the corre-
sponding slice at treatment fraction 9 in the conventional
and proposed plans for one patient (Fig. 4b-c). At simula-
tion, the primary OARs in the conventional case were
assigned weighting parameters based largely upon proxim-
ity to the PTV. Of the four primary OARs, the large bowel
received the second lowest weighting due to the relatively
small fraction of the structure located near the PTV, which
is observable in Fig. 4a. The situation at fraction 9 is
considerably different, as the large bowel now represents a
significant volume in close proximity to the PTV. In the
Table 3 Average coverage in each metric using the conventional
and OAR grouping method over all adapted fractions for each
patient
Adapted
Fractions
Method Average Coverage (%)
PTV OPT PTV
D95 D95 D100
Patient 1
14 Conventional 94.00 77.36 66.47
Proposed 95.78 79.64 69.68
Patient 2
13 Conventional 99.91 82.56 77.97
Proposed 99.65 83.26 79.39
Patient 3
13 Conventional 94.88 84.36 78.89
Proposed 96.85 86.40 80.13
Patient 4
15 Conventional 94.59 81.38 72.19
Proposed 99.48 87.88 84.24
Patient 5
14 Conventional 76.44 48.50 40.42
Proposed 78.49 49.99 43.29
Patient 6
15 Conventional 67.46 49.16 39.64
Proposed 72.62 53.08 43.93
Patient 7
14 Conventional 78.52 76.54 63.09
Proposed 82.32 80.37 69.21
Patient 8
10 Conventional 61.22 52.98 42.57
Proposed 59.21 51.30 41.78
Patient 9
13 Conventional 81.40 67.92 51.71
Proposed 91.22 76.20 63.37
Patient 10
14 Conventional 86.66 70.10 53.97
Proposed 95.60 79.10 67.78
Patient 11
14 Conventional 93.75 70.75 60.51
Proposed 95.66 72.79 65.45
Patient 12
11 Conventional 90.12 80.60 61.67
Proposed 97.30 87.89 80.22
Patient 13
6 Conventional 84.32 61.43 45.89
Proposed 97.99 72.68 62.57
Patient 14
13 Conventional 75.07 51.83 44.00
Table 3 Average coverage in each metric using the conventional
and OAR grouping method over all adapted fractions for each
patient (Continued)
Adapted
Fractions
Method Average Coverage (%)
PTV OPT PTV
D95 D95 D100
Proposed 72.37 50.12 41.84
Patient 15
14 Conventional 75.01 59.78 49.55
Proposed 74.62 59.49 50.00
Patient 16
15 Conventional 79.60 62.28 52.99
Proposed 82.27 64.54 54.92
Table 4 Average, minimum, and maximum coverage differences
between conventional and OAR grouping plans observed over all
patients (n = 16)
Average Minimum Maximum
PTV OPT D95 (%) 3.98 ± 4.97 −2.78 15.87
PTV D95 (%) 3.87 ± 4.29 −1.78 13.07
D100 (%) 6.47 ± 7.16 −2.29 20.19
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Fig. 3 Average change from conventional to OAR grouping plans for each patient plotted for (a) PTV D95 coverage, (b) PTV D100 coverage, and
(c) PTV OPT D95 coverage
Fig. 4 OARs and target structures in one slice at simulation (a) and treatment fraction 9 (b-c) for one patient. The large bowel demonstrates a
large change in volume and proximity to the PTV from simulation to treatment. Isodose lines are displayed for the conventional plan (b) and
the OAR grouping plan (c). The OAR grouping plan demonstrates improved D100 and D95 coverage over the PTV, as well as isodose lines that
are moderately more conformal to the PTV compared to those in the conventional plan
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conventional case, the weighting assigned at simulation
does not reflect the actual anatomy, and the large bowel is
overdosed upon plan re-optimization as a result.
Normalizing the delivered dose such that the large bowel
receives the prescribed limit of 45 Gy to 0.5 cm3, D100
coverage of the PTV is only 14.29% in the conventional
case (Fig. 4b). In contrast, by applying the OAR grouping
method, the optimization function is made somewhat
insensitive to these inter-fractional changes in anatomy
and the resulting coverage demonstrates considerable
improvement. As seen in Fig. 4c, the isodose lines in the
OAR grouping plan are moderately more conformal to
the PTV compared to those in the conventional plan,
resulting in PTV D100 coverage of 74.93% without violating
any OAR dose constraints. The dose-volume histogram
(DVH) presented in Fig. 5 demonstrates improved PTV
coverage and OAR doses that are generally comparable
between the OAR grouping and conventional plans, save
for the small bowel. The dose to the small bowel in this
case, despite being higher in the OAR grouping plan, is
still well below the volumetric dose limit assigned to the
small bowel.
Now, the second scenario of note: for plans in which
the OAR grouping method was approximated by the
conventional objective function through the assignment
of equal or similar weighting to each of the primary
OARs, coverage for the conventional and proposed plans
was generally comparable. It should be noted that the
present study was limited in scope to cases in which in
the volumetric dose constraints assigned to each of the
four primary OARs were the same. Use of the OAR
grouping method in cases where this condition is not
maintained should be investigated further. However, it is
anticipated that the OAR grouping method is valid as
long as there does not exist any drastic difference
between these critical structures.
Conclusions
In this study, the OAR grouping method has been
proposed as a means to simplify the daily adaptive
treatment planning workflow and improve target coverage
in adapted fractions. Characterizing the performance of
OAR grouping plans reveals two scenarios of note. When
the conventional simulation plan favored or disregarded
an OAR through the assignment of distinct weighting
parameters, OAR grouping plans generally demonstrated
improved coverage compared to the conventional plan
due to the decreased sensitivity of the OAR grouping
objective function to inter-fraction anatomical variations.
When the OAR grouping method was approximated by
equal weighting in the conventional plan, coverage was
generally comparable. In any case, the construction of the
initial objective function at simulation is simplified by
combining the four primary OARs in a pancreatic cancer
case. This simplification comes along with an improve-
ment in target coverage over a majority of fractions when
comparing OAR grouping plans to conventional, clinically
delivered plans.
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